TCR gamma/delta bearing lymphocytes in peripheral blood of allogenic bone marrow transplanted patients.

abstract：:Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders. Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantification of survival ...

journal_title：Leukemia

authors： Hehlmann R

更新日期：2000-09-01 00:00:00

abstract：:A 23-year-old male found to have Philadelphia chromosome-positive chronic myeloid leukemia (CML) in May 1987 suffered a myeloid blastic transformation in April 1993. A second chronic phase was achieved after treatment with daunorubicin and cytosine arabinoside and the patient then underwent autologous bone marrow tran...

journal_title：Leukemia

authors： Spencer A,Vulliamy T,Chase A,Goldman JM

更新日期：1995-12-01 00:00:00

abstract：:East Asians, Asian Indians and Amerindians have a five to ten-fold lower age-adjusted incidence rate (AAIR) of chronic lymphocytic leukaemia (CLL) compared with persons of predominately European descent. The data we review suggest a genetic rather than environmental basis for this discordance. All these populations ar...

journal_title：Leukemia

authors： Yang S,Varghese AM,Sood N,Chiattone C,Akinola NO,Huang X,Gale RP

更新日期：2020-10-19 00:00:00

abstract：:Resistant AML encompasses two groups of patients: those with refractory leukemia and those whose leukemia has relapsed. Refractory leukemia is disease that does not respond to initial induction chemotherapy with cytarabine and an anthracycline. Patients with refractory leukemia are likely to have disease with adverse ...

journal_title：Leukemia

authors： Schiller GJ

更新日期：1998-09-01 00:00:00

abstract：:Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma. The starting dose of V was 1.0 mg/m(2) (days 1, 4, 8, 11, every 21 day) with T added f...

journal_title：Leukemia

authors： Pineda-Roman M,Zangari M,van Rhee F,Anaissie E,Szymonifka J,Hoering A,Petty N,Crowley J,Shaughnessy J,Epstein J,Barlogie B

更新日期：2008-07-01 00:00:00

abstract：:Normal human myeloid cells require certain colony stimulating factors (CSFs) for growth and differentiation. These CSFs are normally produced exogenously by accessory cells. However, human acute myeloid leukemia cells have been found, in certain instances, to have constitutive, endogenous production of one or more of ...

journal_title：Leukemia

authors： Ernst TJ,Ritchie AR,O'Rourke R,Griffin JD

更新日期：1989-09-01 00:00:00

abstract：:The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (CDC). We developed a novel strategy to enhance CDC using bispecific antibodies (bsAbs) that neutralize the C-regulators CD55 and CD59 to ...

journal_title：Leukemia

authors： Macor P,Secco E,Mezzaroba N,Zorzet S,Durigutto P,Gaiotto T,De Maso L,Biffi S,Garrovo C,Capolla S,Tripodo C,Gattei V,Marzari R,Tedesco F,Sblattero D

更新日期：2015-02-01 00:00:00

abstract：:We have examined the respiratory status of murine and human marrow progenitor cells proliferating in response to growth factors. Proliferation of fresh marrow cells, which are almost entirely entering terminal differentiation, depends on oxidative phosphorylation as determined by oxygen uptake, lactic acid production,...

journal_title：Leukemia

authors： Garland JM,Katz F

更新日期：1987-07-01 00:00:00

abstract：:Since graft-versus-leukemia (GVL) is the main weapon for disease eradication after reduced intensity conditioning (RIC) allogeneic SCT, the availability of sensitive and specific techniques to monitor changes in tumor load after transplant are especially helpful. These minimal residual disease techniques would allow a...

journal_title：Leukemia

authors： Pérez-Simón JA,Caballero D,Diez-Campelo M,Lopez-Pérez R,Mateos G,Cañizo C,Vazquez L,Vidriales B,Mateos MV,Gonzalez M,San Miguel JF

更新日期：2002-08-01 00:00:00

abstract：:Mesenchymal stromal cells (MSCs) possess broad immunomodulatory capacities that are currently investigated for potential clinical application in treating autoimmune disorders. Third-party MSCs suppress alloantigen-induced proliferation of peripheral blood mononuclear cells providing the rationale for clinical use in g...

journal_title：Leukemia

authors： Malcherek G,Jin N,Hückelhoven AG,Mani J,Wang L,Gern U,Diehlmann A,Wuchter P,Schmitt A,Chen B,Ho AD,Schmitt M

更新日期：2014-12-01 00:00:00

abstract：:Transplantation of normal and malignant human hematopoietic cells into severe combined immunodeficient (SCID) mice allows for evaluation of long-term growth abilities of these cells and provides a preclinical model for therapeutic interventions. However, large numbers of cells are required for successful engraftment i...

journal_title：Leukemia

authors： Terpstra W,Leenen PJ,van den Bos C,Prins A,Loenen WA,Verstegen MM,van Wyngaardt S,van Rooijen N,Wognum AW,Wagemaker G,Wielenga JJ,Löwenberg B

更新日期：1997-07-01 00:00:00

abstract：:Sorafenib, a novel drug for metastatic renal cancer, has broad-spectrum activity against multiple tyrosine kinases, including Raf-1, vascular endothelial growth factor receptor and platelet-derived growth factor receptor. However, little is known about its effects on the immune system. In this report, we examine the e...

journal_title：Leukemia

authors： Zhao W,Gu YH,Song R,Qu BQ,Xu Q

更新日期：2008-06-01 00:00:00

abstract：:We have analyzed the expression of Tdt and CD7 in 335 cases of unequivocal acute myeloid leukemia (AML). Tdt was expressed in 80 (25%) of 321 evaluable cases. Twenty-six of 77 (34%) Tdt+ patients assessable for response, entered complete remission (CR) vs 121 of 209 (58%) Tdt- cases (P < 0.001). CD7 was expressed in 1...

journal_title：Leukemia

authors： Venditti A,Del Poeta G,Buccisano F,Tamburini A,Cox-Froncillo MC,Aronica G,Bruno A,Del Moro B,Epiceno AM,Battaglia A,Forte L,Postorino M,Cordero V,Santinelli S,Amadori S

更新日期：1998-07-01 00:00:00

abstract：:We used a modification of the polymerase chain reaction (PCR) to amplify the specific bcr-abl mRNA from 14 patients with chronic myeloid leukemia (CML) who had previously received non T cell depleted allogenic bone marrow transplantation (BMT). Two types of reactions were used: a single step amplification with 5' and ...

journal_title：Leukemia

authors： Delfau MH,Kerckaert JP,Collyn d'Hooghe M,Fenaux P,Laï JL,Jouet JP,Grandchamp B

更新日期：1990-01-01 00:00:00

abstract：:Blockade of tumor necrosis factor (TNF)alpha by a soluble TNF receptor fusion protein (etanercept; Enbrel) improved in vitro hemopoiesis from the marrow of patients with myelodysplastic syndrome (MDS). Therefore, we enrolled 14 MDS patients (4 RA, 2 RARS, 6 RAEB, 2 CMML), 44-80 (median 60) years old, in a pilot trial....

journal_title：Leukemia

authors： Deeg HJ,Gotlib J,Beckham C,Dugan K,Holmberg L,Schubert M,Appelbaum F,Greenberg P

更新日期：2002-02-01 00:00:00

abstract：:The current study was initiated to compare the anti-lymphoma activity and side-effects of prednimustine/mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) in patients with advanced low-grade non-Hodgkin's lymphomas in way of a prospective randomized multicenter trial. Two hundred and forty-six patie...

journal_title：Leukemia

authors： Unterhalt M,Herrmann R,Tiemann M,Parwaresch R,Stein H,Trümper L,Nahler M,Reuss-Borst M,Tirier C,Neubauer A,Freund M,Kreuser ED,Dietzfelbinger H,Bodenstein H,Engert A,Stauder R,Eimermacher H,Landys K,Hiddemann W

更新日期：1996-05-01 00:00:00

abstract：:Protein phosphatase 2A (PP2A) is a human tumor suppressor that inhibits cellular transformation by regulating the activity of several signaling proteins critical for malignant cell behavior. PP2A has been described as a potential therapeutic target in chronic myeloid leukemia, Philadelphia chromosome-positive acute ly...

journal_title：Leukemia

authors： Cristóbal I,Garcia-Orti L,Cirauqui C,Alonso MM,Calasanz MJ,Odero MD

更新日期：2011-04-01 00:00:00

abstract：:HTLV-1 is an important factor involved in various diseases including adult T-cell leukemia/lymphoma and HTLV-1 associated myelopathy/tropical spastic paraparesis. Amount of HTLV-1 provirus integrated in human peripheral blood mononuclear cells might be a candidate for a risk factor in the manifestation of HTLV-1 assoc...

journal_title：Leukemia

authors： Miwa M,Kushida S,Maeda N,Fang J,Kawamura T,Kameyama T,Uchida K

更新日期：1997-04-01 00:00:00

abstract：:Since in vitro observations indicated that all-trans retinoic acid (ATRA), especially in combination with IFNalpha, can exert significant suppressive effects on Ph+ cells, we investigated the effects and the pharmacokinetic profile of ATRA in a selected cohort of patients with Ph+ chronic myeloid leukemia (CML) in chr...

journal_title：Leukemia

authors： Russo D,Regazzi M,Sacchi S,Visani G,Lazzarino M,Avvisati G,Pelicci PG,Dastoli G,Grandi C,Iacona I,Candoni A,Grattoni R,Galieni P,Rupoli S,Liberati AM,Maiolo AT

更新日期：1998-04-01 00:00:00

abstract：:There is a clear association between the Epstein-Barr virus (EBV) and Hodgkin's disease (HD). EBV is not, however, detectable within the affected tissues of all cases. The proportion of positive cases varies from 15-79% depending on the assay used to detect EBV. The techniques utilised vary not only in sensitivity but...

journal_title：Leukemia

authors： Armstrong AA,Weiss LM,Gallagher A,Jones DB,Krajewski AS,Angus B,Brown G,Jack AS,Wilkins BS,Onions DE

更新日期：1992-09-01 00:00:00

abstract：:This report documents the follow-up information on 69 hairy cell leukemia (HCL) patients treated with interferon alpha-2b (IFN) as primary treatment from 1983-86. Follow-up through October 1991 shows only 11 patients have died. Forty-one of the 57 patients completing the intended 12 or more months of initial IFN treat...

journal_title：Leukemia

authors： Golomb HM,Ratain MJ,Mick R,Daly K

更新日期：1992-11-01 00:00:00

abstract：:The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...

journal_title：Leukemia

authors： Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A,BIOMED-I.

更新日期：2001-08-01 00:00:00

abstract：:A single dominant gene Tlsm-1 was found to determine the type of spontaneous lymphomas to be T in the cross between AKR/Ms and SL/Kh. Microsatellite analysis mapped Tlsm-1 at the position 61 cM from centromere of Chr. 7. Study of this segment of T-lymphoma prone AKXD Rl strains also showed association of Tlsm-1 with T...

journal_title：Leukemia

authors： Hiai H,Yamada Y,Shisa H,Kamoto T,Abujiang P,Lu LM

更新日期：1997-04-01 00:00:00

abstract：:Retinoic acid receptor (RA) heterodimer (RAR/RXR) activities have been shown to be repressed by transcriptional co-repressor, SMRT/N-CoR, in the absence of the ligand while upon all-trans retionic acid (ATRA) treatment, SMRT/N-CoR is dissociated from RARalpha leading to gene expression by the recruitment of transcript...

journal_title：Leukemia

authors： So CW,Dong S,So CK,Cheng GX,Huang QH,Chen SJ,Chan LC

更新日期：2000-01-01 00:00:00

abstract：:The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 ...

journal_title：Leukemia

authors： Platzbecker U,Symeonidis A,Oliva EN,Goede JS,Delforge M,Mayer J,Slama B,Badre S,Gasal E,Mehta B,Franklin J

更新日期：2017-09-01 00:00:00

abstract：:Prevailing wisdom holds that hematopoietic stem cells (HSCs) are predominantly quiescent. Although HSC cycle status has long been the subject of scrutiny, virtually all marrow stem cell research has been based on studies of highly purified HSCs. Here we explored the cell cycle status of marrow stem cells in un-separat...

journal_title：Leukemia

authors： Goldberg LR,Dooner MS,Johnson KW,Papa EF,Pereira MG,Del Tatto M,Adler DM,Aliotta JM,Quesenberry PJ

更新日期：2014-04-01 00:00:00

abstract：:Interferon-alpha produces a complete hematologic and cytogenetic remission in approximately 20% of patients with chronic myelogenous leukemia (CML). In this study, we applied fluorescent in situ hybridization (FISH) methodology to examine the possibility that a low level of proliferating Philadelphia-chromosome-positi...

journal_title：Leukemia

authors： Zhao L,Kantarjian HM,Van Oort J,Cork A,Trujillo JM,Liang JC

更新日期：1993-02-01 00:00:00

abstract：:We applied a new strategy for the detection of N-ras gene mutations based on LightCycler technology. We designed two sets of amplimers and internal hybridization probes representing N-ras codons 12/13 and codon 61, respectively. Genomic DNAs from 134 childhood acute lymphoblastic leukemia (ALL) patients (83 common ALL...

journal_title：Leukemia

authors： Nakao M,Janssen JW,Seriu T,Bartram CR

更新日期：2000-02-01 00:00:00

abstract：:Disturbances in the regulation of the balance between the fibrinolytic and procoagulant properties of leukemic cells may contribute to the coagulopathy of acute leukemia. The coagulant response to a number of stimuli is regulated by the expression of tissue factor, but the role of the plasminogen activator inhibitors,...

journal_title：Leukemia

authors： Dickinson JL,Antalis TM

更新日期：1993-06-01 00:00:00

abstract：:A patient with Philadelphia positive (Ph'+) acute lymphoblastic leukemia (ALL), in remission for over 4 years, developed an acute myeloblastic leukemia (AML), M2-type. During the second disease, the blast cells displayed a typical t(8;21)(q22;q22) translocation, in the absence of the Ph' chromosome. This is the first ...

journal_title：Leukemia

authors： De Cuia MR,Alimena G,Gastaldi R,Spiriti MA,Giona F,Mancini M,Mandelli F

更新日期：1989-04-01 00:00:00